

# Screening for Oral Cancer

## Recommendation Statement

### U.S. Preventive Services Task Force

This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for oral cancer and the supporting scientific evidence, and updates the 1996 recommendations contained in the *Guide to Clinical Preventive Services*, second edition.<sup>1</sup> In 1996, the USPSTF found insufficient evidence to recommend for or against routine screening for oral cancer (C recommendation).<sup>1</sup> Since then, the USPSTF criteria to rate the strength of the evidence have changed.<sup>2</sup> Therefore, this recommendation statement has been updated and revised based on the current USPSTF methodology and rating of the strength of the evidence. Explanations of the current Task Force ratings and of the strength of overall evidence are given in Appendix A and Appendix B, respectively.

The complete information on which this statement is based, including evidence tables and references, is available in the brief update<sup>3</sup> on this topic, on the USPSTF Web site ([www.preventiveservices.ahrq.gov](http://www.preventiveservices.ahrq.gov)). The recommendation statement and brief update are also available in print from the Agency for Healthcare Research and Quality (AHRQ) Publications Clearinghouse (call 1-800-358-9295, or e-mail [ahrqpubs@ahrq.gov](mailto:ahrqpubs@ahrq.gov)). The recommendation is also posted on the Web site of the National Guideline Clearinghouse™ ([www.guideline.gov](http://www.guideline.gov)).

Recommendations made by the USPSTF are independent of the U.S. Government. They should not be construed as an official position of AHRQ or the U.S. Department of Health and Human Services.

## Summary of Recommendation

The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to recommend for or against routinely screening adults for oral cancer.

### **I recommendation.**

*The USPSTF found no new good quality evidence that screening for oral cancer leads to improved health outcomes for either high-risk adults (ie, those over the age of 50 who use tobacco) or for average-risk adults in the general population. It is unlikely that controlled trials of screening for oral cancer will ever be conducted in the general population because of the very low incidence of oral cancer in the United States. There is also no new evidence for the harms of screening. As a result, the USPSTF could not determine the balance between benefits and harms of screening for oral cancer.*

## Clinical Considerations

- Direct inspection and palpation of the oral cavity is the most commonly recommended method of screening for oral cancer, although there are little data on the sensitivity and specificity of this method. Screening techniques other than inspection and palpation are being evaluated but are still experimental.
- Tobacco use in all forms is the biggest risk factor for oral cancer. Alcohol abuse combined with tobacco use increases risk.

---

Corresponding author: Ned Calonge, MD, MPH, Chair, U.S. Preventive Services Task Force, c/o Program Director, USPSTF, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, e-mail: [uspstf@ahrq.gov](mailto:uspstf@ahrq.gov).

- Clinicians should be alert to the possibility of oral cancer when treating patients who use tobacco or alcohol.
- Patients should be encouraged to not use tobacco and to limit alcohol use in order to decrease their risk for oral cancer as well as heart disease, stroke, lung cancer, and cirrhosis.

## References

1. U.S. Preventive Services Task Force. *Guide to Clinical Preventive Services*. 2nd ed. Washington, DC: Office of Disease Prevention and Health Promotion, 1996.
2. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D; Methods Work Group, Third U.S. Preventive Services Task Force. Current methods of the U.S. Preventive Services Task Force: a review of the process. *Am J Prev Med*. 2001;20(3S):21–35.
3. Screening for oral cancer: a brief evidence update for the U.S Preventive Services Task Force. Agency for Healthcare Research and Quality. 2004. Available at <http://www.preventiveservices.ahrq.gov>.

## Appendix A U.S. Preventive Services Task Force—Recommendations and Ratings

The Task Force grades its recommendations according to one of 5 classifications (A, B, C, D, I) reflecting the strength of evidence and magnitude of net benefit (benefits minus harms):

- A. The USPSTF strongly recommends that clinicians provide [the service] to eligible patients. *The USPSTF found good evidence that [the service] improves important health outcomes and concludes that benefits substantially outweigh harms.*
- B. The USPSTF recommends that clinicians provide [the service] to eligible patients. *The USPSTF found at least fair evidence that [the service] improves important health outcomes and concludes that benefits outweigh harms.*
- C. The USPSTF makes no recommendation for or against routine provision of [the service]. *The USPSTF found at least fair evidence that [the service] can improve health outcomes but concludes that the balance of benefits and harms is too close to justify a general recommendation.*
- D. The USPSTF recommends against routinely providing [the service] to asymptomatic patients. *The USPSTF found at least fair evidence that [the service] is ineffective or that harms outweigh benefits.*
- I. The USPSTF concludes that the evidence is insufficient to recommend for or against routinely providing [the service]. *Evidence that [the service] is effective is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.*

## Appendix B U.S. Preventive Services Task Force—Strength of Overall Evidence

The USPSTF grades the quality of the overall evidence for a service on a 3-point scale (good, fair, poor):

- Good:** Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.
- Fair:** Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes.
- Poor:** Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.

### Members of the U.S. Preventive Services Task Force\*

**Alfred O. Berg, MD, MPH, Chair, USPSTF** (Professor and Chair, Department of Family Medicine, University of Washington, Seattle, WA)

**Janet D. Allan, PhD, RN, CS, Vice-chair, USPSTF** (Dean, School of Nursing, University of Maryland, Baltimore, Baltimore, MD)

**Ned Calonge, MD, MPH** (Acting Chief Medical Officer and State Epidemiologist, Colorado Department of Public Health and Environment, Denver, CO)

**Paul S. Frame, MD** (Family Physician, Tri-County Family Medicine, Cohocton, NY, and Clinical Professor of Family Medicine, University of Rochester, Rochester, NY)

**Joxel Garcia, MD, MBA** (Deputy Director, Pan American Health Organization, Washington, DC)

**Russell Harris, MD, MPH** (Associate Professor of Medicine, Sheps Center for Health Services Research, University of North Carolina School of Medicine, Chapel Hill, NC)

**Mark S. Johnson, MD, MPH** (Professor and Chair, Department of Family Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ)

**Jonathan D. Klein, MD, MPH** (Associate Professor, Department of Pediatrics, University of Rochester School of Medicine, Rochester, NY)

**Carol Loveland-Cherry, PhD, RN** (Executive Associate Dean, School of Nursing, University of Michigan, Ann Arbor, MI)

**Virginia A. Moyer, MD, MPH** (Professor, Department of Pediatrics, University of Texas Health Science Center, Houston, TX)

**C. Tracy Orleans, PhD** (Senior Scientist, The Robert Wood Johnson Foundation, Princeton, NJ)

**Albert L. Siu, MD, MSPH** (Professor and Chairman, Brookdale Department of Geriatrics and Adult Development, Mount Sinai Medical Center, New York, NY)

**Steven M. Teutsch, MD, MPH** (Executive Director, Outcomes Research and Management, Merck & Company, Inc., West Point, PA)

**Carolyn Westhoff, MD, MSc** (Professor of Obstetrics and Gynecology and Professor of Public Health, Columbia University, New York, NY)

**Steven H. Woolf, MD, MPH** (Professor, Department of Family Practice and Department of Preventive and Community Medicine and Director of Research, Department of Family Practice, Virginia Commonwealth University, Fairfax, VA)

\*Members of the Task Force at the time this recommendation was finalized. For a list of current Task Force members, go to [www.ahrq.gov/clinic/uspstfab.htm](http://www.ahrq.gov/clinic/uspstfab.htm).